Universidad Peruana Cayetano Heredia

SGLT-2 inhibitors for people with type 2 diabetes.

Mostrar el registro sencillo del ítem

dc.contributor.author Málaga Rodríguez, Germán Javier
dc.contributor.author Ruiz, Eloy F.
dc.date.accessioned 2019-12-06T20:57:42Z
dc.date.available 2019-12-06T20:57:42Z
dc.date.issued 2019
dc.identifier.uri https://hdl.handle.net/20.500.12866/7365
dc.description.abstract Evidence that sodium-glucose co-transporter-2 inhibitors (SGLT2i) can reduce cardiovascular risk—with trials showing reductions in cardiovascular death, myocardial infarction, and stroke—would suggest they have much to offer in the care of patients with type 2 diabetes at high risk of cardiovascular events. But should they be used in patients at low risk?... en_US
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartofseries Lancet
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Diabetes Mellitus, Type 2 en_US
dc.subject Dipeptidyl-Peptidase IV Inhibitors en_US
dc.subject Sodium-Glucose Transporter 2 Inhibitors en_US
dc.subject acetylsalicylic acid en_US
dc.subject acute heart failure en_US
dc.subject antidiabetic agent en_US
dc.subject cardiovascular disease en_US
dc.subject cause of death en_US
dc.subject Diabetes Mellitus, Type 2 en_US
dc.subject dipeptidyl peptidase IV inhibitor en_US
dc.subject Dipeptidyl-Peptidase IV Inhibitors en_US
dc.subject disease course en_US
dc.subject geriatric disorder en_US
dc.subject heart failure with preserved ejection fraction en_US
dc.subject heart failure with reduced ejection fraction en_US
dc.subject heart infarction en_US
dc.subject human en_US
dc.subject Humans en_US
dc.subject hydroxymethylglutaryl coenzyme A reductase inhibitor en_US
dc.subject Hypoglycemic Agents en_US
dc.subject intervention study en_US
dc.subject kidney function en_US
dc.subject Letter en_US
dc.subject multiple chronic conditions en_US
dc.subject non insulin dependent diabetes mellitus en_US
dc.subject patient care en_US
dc.subject personalized medicine en_US
dc.subject priority journal en_US
dc.subject risk factor en_US
dc.subject risk reduction en_US
dc.subject secondary prevention en_US
dc.subject Secondary Prevention en_US
dc.subject sodium glucose cotransporter 2 inhibitor en_US
dc.subject Sodium-Glucose Transporter 2 Inhibitors en_US
dc.title SGLT-2 inhibitors for people with type 2 diabetes. en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1016/S0140-6736(19)30720-2
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.00
dc.relation.issn 1474-547X


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas